• CalendarApril 5, 2021 – "An Overview of the Patent Systems In Brazil and India and the Recent Attacks Against Them" (Dannemann Siemsen) – 9:30 am (ET)

    April 6, 2021 – "The Pharma and Biologics Challenges" (Federal Circuit Bar Association) – 9:00 to 10:00 am (ET)

    April 7, 2021 – "How to Plan and Assess an Investment — Friendly IP Strategy — Due Diligence Pitfalls" (Luzzatto & Luzzatto) – 9:00 to 10:00 am (EST)

    April 7, 2021 – "Opportunities for Patent Applicants in Latin America: Benefiting from Work Sharing Programs and Other Fast-Track Options" (Intellectual Property Owners Association) – 2:00 pm to 3:00 pm (ET)

    April 16, 2020 – "Strategies for Federal Circuit, District Court, ITC, and PTAB" (UIC John Marshall Law School Center for Intellectual Property, Information & Privacy Law) – 7:40 am to 3:15 pm

    April 26-27, 2021 – Paragraph IV Disputes Conference (American Conference Institute)

  • IPO #2The Intellectual Property Owners Association (IPO) will offer a one-hour webinar entitled "Opportunities for Patent Applicants in Latin America: Benefiting from Work Sharing Programs and Other Fast-Track Options" on April 7, 2021 from 2:00 pm to 3:00 pm (ET).  Jesus Hernandez, Office of Policy & International Affairs, U.S. Patent and Trademark Office will provide an overview of the PPH programs in Latin America, and explain the PPG agreement between the USPTO and the Mexican PTO (IMPI); Diego Musskopf, Deputy Head of the Special Patent Affairs Service, INPI-BR will discuss the success of the PPH pilot program, explain other fast-track options currently available, and show the results of the Program for Tackling the Backlog; and Ricardo Nunes of Daniel Law will share insights from a practitioner's perspective managing patent portfolios in Latin America.

    The registration fee for the webinar is $150 for non-members or free for IPO members (government and academic rates are available upon request).  Those interested in registering for the webinar can do so here.

  • Federal Circuit Bar Association_2The Federal Circuit Bar Association (FCBA) will be offering a remote program entitled "The Pharma and Biologics Challenges" on April 6, 2021 from 9:00 to 10:00 am (ET).  Ute Kilger of Boehmert & Boehmert will moderate a panel consisting of Christof Bull of UCB, Paul Higgins of Johnson & Johnson, Jane Licata of Licata & Tyrrell, and Corey Salsberg of Novartis.

    There is no registration fee for FCBA and EPLAW members and the registration for non-members is $75.  Additional information regarding the program can be found here.

  • Luzzatto & LuzzattoLuzzatto & Luzzatto will be offering a webinar entitled "How to Plan and Assess an Investment — Friendly IP Strategy — Due Diligence Pitfalls" on April 7, 2021 from 9:00 to 10:00 am (EST).  Kfir Luzzatto of The Luzzatto Group and Ehud Laszlo of Luzzatto Law Firm will provide tips and case studies that analyze common pitfalls in the due diligence process from both sides.  Specific recommendations will be included for planning an investment-friendly IP strategy and improving the assessment of investment-unfriendly IP of target companies.  Additional emphasis will be placed on the connection between an investment-oriented IP strategy and the resulting commercial agreements.

    Those wishing to register can do so here.

  • Dannemann SiemsenDannemann Siemsen will be offering a webinar entitled "An Overview of the Patent Systems In Brazil and India and the Recent Attacks Against Them" on April 5, 2021 at 9:30 am (ET).  Gustavo Morais, Goutam Bhattacharyya, Luiz Augusto Lopes Paulino, and Sanjeev K Tiwari of Dannemann Siemsen will discuss India's and Brazil's patent systems and how they are being challenged lately through initiatives related to compulsory licenses and patent term reduction.

    Those wishing to register can do so here.

  • By Kevin E. Noonan

    USPTO SealThe U.S. Patent and Trademark Office Patent Trial and Appeal Board (PTAB) has issued a notice of extension of certain deadlines by party stipulation in the two interferences involving ToolGen Inc. as Senior Party (No. 106,126 with The Broad Institute, the Massachusetts Institute of Technology, and Harvard College as Junior Party, and No. 106,127 naming the University of California, Berkeley, the University of Vienna, and Emmanuelle Charpentier ("CVC") as Junior Party).

    The deadlines for Time Periods 1-5 in the '126 Interference have been extended as follows:

    TIME PERIOD 1 ……………………………………………………….9 April 2021
    File motions                                                                                  28 May 2021
    File (but serve one business day later) priority statements

    TIME PERIOD 2 ……………………………………………………….14 May 2021
    File responsive motions to motions filed in TIME PERIOD 1             22 June 2021

    TIME PERIOD 3 ………………………………………………………25 June 2021
    File oppositions to all motions                                                       30 July 2021

    TIME PERIOD 4 ……………………………………………………..6 August 2021
    File all replies                                                                     10 September 2021

    TIME PERIOD 5 ……………………………………………….17 September 2021
    File request for oral argument                                             24 September 2021
    File motions to exclude
    File observations

    TIME PERIOD 6 …………………………………………………..8 October 2021
    File oppositions to motions to exclude
    File response to observations

    TIME PERIOD 7 ………………………………………………….15 October 2021
    File replies to oppositions to motions to exclude

    DEFAULT ORAL ARGUMENT DATE ……………………………………………TBD

    The deadlines for Time Periods 1-3 in the '127 Interference have been extended as follows:

    TIME PERIOD 1 ……………………………………………………….9 April 2021
    File motions                                                                                  20 May 2021
    File (but serve one business day later) priority statements

    TIME PERIOD 2 ……………………………………………………….14 May 2021
    File responsive motions to motions filed in TIME PERIOD 1             11 June 2021

    TIME PERIOD 3 ………………………………………………………25 June 2021
    File oppositions to all motions                                                         1 July 2021

    TIME PERIOD 4 ……………………………………………………..6 August 2021
    File all replies

    TIME PERIOD 5 ………………………………………………..17 September 2021
    File request for oral argument
    File motions to exclude
    File observations

    TIME PERIOD 6 …………………………………………………….8 October 2021
    File oppositions to motions to exclude
    File response to observations

    TIME PERIOD 7 ……………………………………………………15 October 2021
    File replies to oppositions to motions to exclude

    DEFAULT ORAL ARGUMENT DATE ……………………………………………..TBD

    The Board's notice for each Interference contained no explanation for these changes other than the parties' stipulations.

  • By Kevin E. Noonan

    SARS-CoV-2A recent COVID post elicited the comment that we were just a "ray of sunshine."  Following in this tradition, this post concerns a recent report, in PLOS Biology, that the evolution of the SARS-CoV-2 virus (which causes COVID-19) evinced the development of a "highly efficient human pathogen" (to quote Billie Eilish, "Duh!").

    The paper, entitled "Natural selection in the evolution of SARS-CoV-2 in bats created a generalist virus and highly capable human pathogen," was reported by an international team* of researchers.  It was known prior to this work that SARS-CoV-2 and the virus that caused the SARS outbreak in 2002-2003 (which these authors term "SARS-CoV-1" to avoid confusion) arose in bats, and that SARS-CoV-2 is particularly infective in humans, inter alia, for having a furin protease cleavage site (Arg-X-X-Arg/ Arg-X-Arg/Lys-Arg) in its Spike protein, which facilitates protease-related binding to human angiotensin-converting enzyme 2 (ACE2) because furin is expressed in human lung tissue.  The interesting conclusions drawn by these authors is that mutational adaptations that facilitate human infection by the virus occurred prior to the jump from bats to humans, which accounts (at least in part) for the rapid dissemination/infectivity in the pandemic because the virus did not require long-term incubation to achieve the species switch typical of other zoonotic viruses.  Specifically, the authors report:

    [U]nlike most other RNA viruses which acquire adaptations after switching to a new host species for efficient replication and spreading as successfully as exhibited by SARS-CoV-2, the Sarbecoviruses [a closely related bat viral species]—which already transmit frequently among bat species—can exploit the generalist properties of their ACE2 binding ability, facilitating successful infection of non-bat species, including humans.

    The paper reports these researchers' comparison between signs of positive selection during the pandemic with historic selection in related bat viruses.  They assessed 133,741 SARS-CoV-2 virus samples collected in the first 11 months of the pandemic with 69 samples of related (Sarbecovirus) virus genomes for the frequencies of nonsynonymous (dN) mutations (which result in amino acid sequence differences that can be subject to selective pressures) with synonymous (dS) mutations (which change at the nucleic acid but not amino acid sequence).  Nonsynonymous mutations were expected to arise (i.e., be detected) more slowly in the viral population, because while both synonymous and nonsynonymous changes arise "randomly" there is no basis for selection of synonymous ones.  As expected, dN mutations arose at 4% the rate of dS when comparing SARS-CoV-2 with related bat Sarbecovirus RaTG13.  The authors further report that "[t]he vast majority of 20,687 observed mutations occur at very low frequency, with 79% of mutations observed in 10 or fewer of the 133,741 SARS-CoV-2 genome sequences analysed."  They conclude from these data that "SARS-CoV-2 is evolving relatively slowly with no dramatic increases in selective pressures occurring over the sampling period [from] December 2019 to October 2020."

    Perhaps surprisingly, the D614G mutation, putatively associated with higher rates of infection (see "The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity"), was detected in samples collected early in the pandemic, whereas other mutated sites occurred later, suggesting that the D614G variant has a higher capacity for positive selection in unvaccinated/uninfected populations because it has had a longer time to spread through the virus populations.  In addition, these researchers found that most of the other mutations were only transiently present in the viral population.

    In comparisons with other bat viruses, "diversifying" selection, associated with the ability of the virus to "jump" species, was found in the earliest branches of virus evolution from the bat virus.  These researchers further report that there was "no evidence of selection in the terminal branch leading to SARS-CoV-2[, c]onsistent with the nonhuman progenitor of SARS-CoV-2 requiring little or no novel adaptation to successfully infect humans" (although they also caution that "no model can detect all signatures of historic genomic adaptation, and mutations which may enable SARS-CoV-2 to infect humans could have arisen by genetic drift in the reservoir host before human exposure").

    Also found was evidence of a related bat virus, RmYN02, that has a sequence in comparison with SARS-CoV-2 that indicates recombination with prototype of SARS-CoV-2 as early as 1976, evidence of how long this virus was "brewing" in bat populations over time and consistent with "direct" bat-to-human transmission; indeed, the researchers found no evidence that related viruses are found in pangolins.

    Further (and having the character of improvident destiny or the propensity for God to play dice contrary to Einstein's preferences), the sequence comparisons with bat viruses are consistent not with sequence changes related to a change in host species (from bat to human) but more consistent with a history of sequence changes related to the bat host(s) (such as immune avoidance or tissue preferences) having arisen that "preselected" the virus for effective human infection.  As these authors write:  "[t]hese results suggest that the majority of adaptive changes which generated SARS-CoV-2 took place prior to its emergence in the human population."

    Exceptions are the mutations related to UK (B.1.1.7) or South African (B.1.351) mutations, which seem associated with "host immunity due to previous exposure and/or chronic infections of probably immunocompromised individuals," i.e., mutations more in line with conventional stories of how zoonotic viruses show sequence changes related to adaptation to a new host.

    There has been evidence supporting these conclusions (outside the depth of the genetic analyses presented here; see "Sequence Comparisons Illustrate Susceptibility to Coronavirus Infection") regarding the biology of the observed ease of transmission to other hosts due to evolution of a "generalist" virus that arose in bats.  In this regard, the authors state "[t]he apparent 'success' of these bat viruses to transmit to multiple other mammals and spread with few to no significant genomic changes further supports the hypothesis that the SARS-CoV-2 progenitor is from a viral lineage with a relatively generalist nature."  This is consistent with a mechanism wherein this "generalist" virus arose in bat populations over the past ~100 years as a function of host switching or tissue tropism within bat species, perhaps due to resistance in bats (see "How Bats Are Different").

    Finally, and consistent with these ideas, the authors present a histogram of the various related coronavirus species showing the genetic distance between SARS-CoV-1 and SARS-CoV-2 and illustrating that the genetic changes characterizing the increased human infectivity of SARS-CoV-2 arose late in the evolution of this species.

    2021-03-31 Image
    The authors conclude with a cautionary note:

    An overarching point stemming from these observations is the lack of sampling and knowledge of the diversity in this viral subgenus.  In particular, the closest known bat viruses to SARS-CoV-2 are relatively divergent in time[], and the apparent generalist nature of these viruses suggests that there are species of wild mammals, yet to be sampled, infected with nCoV-like viruses.  Serological studies of communities in China that come into contact with bats indicate that incidental and dead-end spillover of SARS-like viruses into humans do occur[].  Due to the high diversity and generalist nature of these Sarbecoviruses, a future spillover, potentially coupled with a recombination event with SARS-CoV-2, is possible, and such a "SARS-CoV-3" emergence could be sufficiently divergent to evade either natural or vaccine-acquired immunity, as demonstrated for SARS-CoV-1 versus SARS-CoV-2.  We must therefore dramatically ramp up surveillance for Sarbecoviruses at the human–animal interface and monitor carefully for future SARS-CoV emergence in the human population.

    * MRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom; Temple University, Institute for Genomics and Evolutionary Medicine, Philadelphia, Pennsylvania; Center for Infectious Disease Dynamics, Department of Biology, Pennsylvania State University, University Park, Pennsylvania; Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium

  • By Donald Zuhn

    Washington - White House #3Earlier today, a group of fifteen industry and trade organizations sent a letter to five members of the Biden Administration, to express their strong support for the Administration's work to leverage international mechanisms to help address COVID-19 and also for the Administration's continued efforts to oppose "a problematic proposal at the World Trade Organization to waive IP global protections," which would "remov[e] patent, industrial designs, copyright, and trade secret protection for any products and services so long as they can be tied to COVID-19."

    The letter's signatories included the Advanced Medical Technology Association (AdvaMed), Biotechnology Innovation Organization (BIO), Incubate Coalition, Latino Coalition, National Association of Manufacturers (NAM), National Foreign Trade Council (NFTC), National LGBT Chamber of Commerce (NGLCC), National Puerto Rican Chamber of Commerce, Pharmaceutical Research and Manufacturers of America (PhRMA), Small Business & Entrepreneurship Council (SBE), Software and Information Industry Association (SIIA), Telecommunications Industry Association (TIA), U.S. Chamber of Commerce, U.S. Council for International Business (USCIB), and U.S. Pan Asian American Chamber of Commerce (USPAACC).  The coalition's letter was addressed to Gina M. Raimondo, Secretary of Commerce; Katherine C. Tai, U.S. Trade Representative; Brian Deese, Assistant to the President for Economic Policy; Jeffrey Zients, Coordinator of the COVID-19 Response and Counselor to the President; and Jacob Sullivan, Assistant to the President for National Security Affairs.

    The letter begins by noting that "[n]o country will be safe, until the virus is controlled everywhere, including at home and abroad, in developed and developing countries," and acknowledging "robust U.S. leadership" in global efforts to ramp-up the development and manufacturing of COVID-19 supplies and treatments to defeat the pandemic.  The coalition states that the U.S. "has led the world in promoting policies that advance scientific innovation, improve global health, and foster economic growth," and points out that "[t]hese policies have created R&D-intensive industries that contribute $6 trillion towards the U.S. gross domestic product and support approximately 45 million U.S. jobs in all 50 states."

    The letter also commends the country's innovative companies for responding to the COVID-19 pandemic by "leverage[ing] their extraordinary R&D capacity to launch the unprecedented development and delivery of diagnostics, medical equipment, treatments, vaccines, digital tools, and information sharing faster than ever before."  The coalition suggests, however, that this response would not have been possible without a robust IP environment in the U.S.  The coalition also expresses support for one of the Administration's most recent COVID-19 vaccine global initiatives — joining with Australia, India, and Japan to expand manufacturing and distribution of COVID-19 vaccines in the Indo-Pacific region.

    Turning to the WTO waiver proposal (which we discussed here), the coalition writes that:

    Unfortunately, some countries have chosen this moment to pursue their longstanding goals to weaken IP rights, including through a problematic proposal at the World Trade Organization to waive IP global protections.  This waiver is as vague as it is broad, removing patent, industrial designs, copyright, and trade secret protection for any products and services so long as they can be tied to COVID-19.  Proponents of the waiver have claimed, without evidence, that it would advance public health.  In reality, the waiver would undermine the global response to COVID-19 and would not achieve its stated goal to rapidly expand vaccines production.

    The letter adds that the WTO waiver proposal distracts from addressing the manufacturing and logistical issues that constitute "[t]he greatest barriers to faster global access to vaccines and therapies."

    The coalition concludes its letter by expressing support for "the Administration's global leadership and collaboration with key global vaccine mechanisms, consistent focus on efforts to identify and eliminate the real barriers to end the pandemic and ensure faster global vaccination, and continued efforts to oppose this waiver."  The letter also encourages the Administration to continue to oppose the WTO waiver proposal, and to continue to work with Japan, the European Union, the United Kingdom, Switzerland, and Brazil "to foster a more productive, comprehensive conversation" with WTO Director-General Ngozi Okonjo-Iweala "about ensuring equitable access to COVID-19 products by tackling trade barriers."

    Logos

  • By Kevin E. Noonan

    USPTO SealExactly two weeks after affirming a decision by the U.S. Patent and Trademark Office Patent Trial and Appeal Board (PTAB) rejecting claims for failure to satisfy the subject matter eligibility standard under 35 U.S.C. § 101, in ex parte examination of claims to methods and related computing systems for genetic haplotyping in In re Board of Trustees of the Leland Stanford Junior University,  the Federal Circuit again affirmed the PTAB's rejection of claims for failure to satisfy the subject matter eligibility standard under 35 U.S.C. § 101, in ex parte examination of claims expressly directed to computerized methods for genetic haplotyping in In re Board of Trustees of the Leland Stanford Junior University, raising sure citation confusion in the future.

    The claimed method is recited in representative claim 1:

    1.  A computerized method for inferring haplotype phase in a collection of unrelated individuals, comprising:
        receiving genotype data describing human genotypes for a plurality of individuals and storing the genotype data on a memory of a computer system;
        imputing an initial haplotype phase for each individual in the plurality of individuals based on a statistical model and storing the initial haplotype phase for each individual in the plurality of individuals on a computer system comprising a processor a memory [sic];
        building a data structure describing a Hidden Markov Model, where the data structure contains:
            a set of imputed haplotype phases comprising the imputed initial haplotype phases for each individual in the plurality of individuals;
            a set of parameters comprising local recombination rates and mutation rates;
        wherein any change to the set of imputed haplotype phases contained within the data structure automatically results in re-computation of the set of parameters comprising local recombination rates and mutation rates contained within the data structure;
        repeatedly randomly modifying at least one of the imputed initial haplotype phases in the set of imputed haplotype phases to automatically re-compute a new set of parameters comprising local recombination rates and mutation rates that are stored within the data structure;
        automatically replacing an imputed haplotype phase for an individual with a randomly modified haplotype phase within the data structure, when the new set of parameters indicate that the randomly modified haplotype phase is more likely than an existing imputed haplotype phase;
        extracting at least one final predicted haplotype phase from the data structure as a phased haplotype for an individual; and
        storing the at least one final predicted haplotype phase for the individual on a memory of a computer system.

    As explained in the opinion, the claims are directed to "computerized statistical methods for determining haplotype phase, which is 'a process for determining the parent from whom alleles—i.e., versions of a gene—are inherited.'"  The opinion further characterizes the invention as:

    The written description of the '982 application explains that accurately estimating haplotype phase based on genotype data obtained through sequencing an individual's genome "plays pivotal roles in population and medical genetic studies."  . . .  The '982 application is directed to methods for inferring haplotype phase in a collection of unrelated individuals.  . . .  According to the written description, although high-throughput DNA sequencing methods provide genotype data for individuals, those methods do not provide haplotype information.  . . .  Though difficult, it is possible to infer haplotype phase, even without information about relatives, using statistics based algorithms.  . . .  Prior art methods for performing this analysis include PHASE, fastPHASE, and Beagle.  . . .  These methods involve using, among other things, a hidden Markov model ("HMM"), which is a statistical tool used in various applications to make probabilistic determinations of latent variables.

    The opinion then describes embodiments of the claimed methods in further detail but the relevant characterization of these methods are that they involve "abstract mathematical algorithms and mental processes," the basis relied upon by the Examiner and affirmed by the PTAB.  According to the Federal Circuit's opinion, the Examiner and the Board applied the two-step test set forth by the Supreme Court in Alice Corp. Pty. Ltd. v. CLS Bank Int'l, 573 U.S. 208 (2014), in making this determination.  With regard to step 1 of the test, the Examiner and Board determined that all steps recited in claim 1 were "directed to . . . abstract ideas in the form of mathematical concepts, i.e., mathematical relationship, formulas, equations, and calculations" and specifically "an initial step of receiving genotype data, followed by the mathematical operations of building a data structure describing an HMM and randomly modifying at least one imputed haplotype to automatically recompute the HMM's parameters."  Indeed, the Board concluded that claim 1 recited two abstract mental processes, viz., a step of "imputing an initial haplotype phase for each individual in the plurality of individuals based on a statistical model"; this step does not require computer implementation.  The second abstract mental process, on the other hand, does require a computer, "automatically replacing an imputed haplotype phase with a randomly modified haplotype phase when the latter is more likely correct than the former."  The remaining elements in the claim merely recite "generic steps of receiving and storing genotype data in a computer memory, extracting the predicted haplotype phase from the data structure, and storing it in a computer memory."  The Board rejected Stanford's contention that these steps enhanced computer functionality and thus rendered the claim patent-eligible, in analogy to Enfish, LLC v. Microsoft Corp., based on lack of specific disclosure in the specification to support improved computer functionality.  For similar reasons, the Board rejected Stanford's reliance on McRO, Inc. v. Bandai Namco Games America Inc. to satisfy the first prong of the Alice test.

    Turning to step two of the Alice analysis, the Board concluded that the claims did not satisfy these requirements either, because the recited steps of receiving, storing, and extracting data were "well-known, routine, and conventional."  Likewise, the Board was not convinced that the specific steps as recited in the claim satisfied this prong, because "although the abstract computational steps 'might be a highly significant discovery in the field of haplotype prediction,' that alone is insufficient to establish patent eligibility."  Completing the patent ineligibility trifecta, the Board relied on Ariosa v. Sequenom for the principle that "the absence of complete preemption does not demonstrate patent eligibility."  This appeal followed.

    The Federal Circuit affirmed in an opinion by Judge Reyna joined by Chief Judge Prost and Judge Lourie (the same panel that rendered the earlier decisions; indeed, the appeals were heard jointly).  As in the earlier opinion, the panel here recited the Court's familiar litany of purported obeisance to the Supreme Court's subject matter eligibility jurisprudence.  Here, the basis of the opinion was evident on the face of the claims:  as the opinion states, "the claims are directed to the use of mathematical calculations and statistical modeling" and "[c]ourts have long held that mathematical algorithms for performing calculations, without more, are patent ineligible under § 101," citing Parker v. Flook, 437 U.S. 584, 595 (1978); Gottschalk v. Benson, 409 U.S. 63, 71–72 (1972); and (for good measure and to blunt the Court's frank obeisance) In re Schrader, 22 F.3d 290, 294 (Fed. Cir. 1994).  After reciting elements of claim 1, the panel opined that "[t]hese generic steps of implementing and processing calculations with a regular computer do not change the character of claim 1 from an abstract idea into a practical application."  According to the panel, the only application of these algorithms in claim 1 was storage of the haplotype phase.  Neither did the panel find that the claims recited any improvement in performance of a generic computer (although being aided in this regard by Stanford's failure to raise this argument before the Board).  The opinion nicely illustrates the difference between claims to methods wherein the outcome of the method is improved (which is not otherwise patent-eligible) and claims to methods that improve performance of a general purpose computer per se (which can be patent eligible), citing McRO, Enfish, Finjan, Inc. v. Blue Coat Sys., Inc., and CardioNet, LLC v. InfoBionic, Inc.  The distinction with the former is that there "the improvement in computational accuracy alleged here does not qualify as an improvement to a technological process; rather, it is merely an enhancement to the abstract mathematical calculation of haplotype phase itself," citing Athena Diagnostics, Inc. v. Mayo Collaborative Servs., LLC and Synopsys, Inc. v. Mentor Graphics Corp.

    With regard to step 2 of the Alice test (which the panel asserts "is like a lifeline: it can rescue and save a claim that has been deemed, at step one, directed to non-statutory subject matter"), the Court concluded that the claims are not saved in this instance.  The reasons:

    • "We find no inventive concept that would warrant treating the use of the claimed algorithms and mathematical calculations as patent eligible subject matter.

    • Further, the recited steps of receiving, extracting, and storing data amount to well known, routine, and conventional steps taken when executing a mathematical algorithm on a regular computer.

    • Using a conventional computer to receive, extract, and store information does not transform an abstract idea into patent eligible subject matter."

    And as has frequently been the case, applicant's assertions in the specification, intended to provide a broad scope to the claims, provide their Achille's heal, wherein the panel asserted that "[t]he written description further illustrates that the mathematical steps performed and the data received are conventional and well understood in the prior art."  The Federal Circuit also states that "it is hard to imagine a patent claim that recites hardware limitations in more generic terms than the terms employed by claim 1."

    Finally, the panel rejected Stanford's argument that the claims recite an ordered combination of steps sufficient to impart patent eligibility.  On the contrary, in the panel's view ("We are not persuaded"),

    The Board correctly determined that claim 1 simply appends the abstract calculations to the well-understood, routine, and conventional steps of receiving and storing data in a computer memory and extracting a predicted haplotype.  The application of those elements results in the mathematical analysis itself, and therefore the claimed method subsists in "the basic tools of scientific and technological work.  . . .  Such basic tools are not patent eligible.

    And applying the judicial coup de gras, regarding Stanford's argument that this ordered combination is novel, the panel asserts "[n]or is novelty the touchstone of patent eligibility.  That a specific or different combination of mathematical steps yields more accurate haplotype predictions than previously achievable under the prior art is not enough to transform the abstract idea in claim 1 into a patent eligible application," citing SAP Am., Inc. v. InvestPic, LLC.

    As with this panel's first opinion on this technology, nothing about this decision is surprising.  U.S. patent law has come to a pretty pass when seemingly the only hope is that the Supreme Court will grant certiorari in American Axle & Mfg. v. Neapco Holdings to perhaps straighten out the illogical morass that is subject matter eligibility at the Federal Circuit.  But it is where we are.

    For comparison, the representative claim recited in the first opinion reads as follows:

    1.  A method for resolving haplotype phase, comprising:
        receiving allele data describing allele information regarding genotypes for a family comprising at least a mother, a father, and at least two children of the mother and the father, where the genotypes for the family contain single nucleotide variants and storing the allele data on a computer system comprising a processor and a memory;
        receiving pedigree data for the family describing information regarding a pedigree for the family and storing the pedigree data on a computer system comprising a processor and a memory;
        determining an inheritance state for the allele information described in the allele data based on identity between single nucleotide variants contained in the genotypes for the family using a Hidden Markov Model having hidden states implemented on a computer system comprising a processor and a memory,
            wherein the hidden states comprise inheritance states, a compression fixed error state, and a[ Mendelian inheritance error]-rich fixed error state,
            wherein the inheritance states are maternal identical, paternal identical, identical, and non-identical;
        receiving transition probability data describing transition probabilities for inheritance states and storing the transition probability data on a computer system comprising a processor and a memory;
        receiving population linkage disequilibrium data and storing the population disequilibrium data on a computer system comprising a processor and a memory;
        determining a haplotype phase for at least one member of the family based on the pedigree data for the family, the inheritance state for the information described in the allele data, the transition probability data, and the population linkage disequilibrium data using a computer system comprising a processor and a memory;
        storing the haplotype phase for at least one member of the family using a computer system comprising a processor and a memory; and
        providing the stored haplotype phase for at least one member of the family in response to a request using a computer system comprising a processor and a memory.

    In re Board of Trustees of the Leland Stanford Junior University (Fed. Cir. 2021)
    Panel: Chief Judge Prost and Circuit Judges Lourie and Reyna
    Opinion by Circuit Judge Reyna

  • CalendarMarch 30, 2021 – "Pragmatic Annuity Decisions: Tips for Making Responsible Pruning Decisions" (IPWatchdog and Anaqua) – 12:00 pm (ET)

    March 30, 2021 – "Quantifying Lost Profits in the COVID-19 World" (Fox Forensic Accounting) – 1:00 pm (ET)

    March 30, 2021 – "52 Years After Killing Licensee Estoppel, Will the Supreme Court Spare Assignor Estoppel?" (Intellectual Property Owners Association) – 2:00 pm to 3:00 pm (ET)

    March 31, 2021 – "Lessons from Successful Innovative Women" (U.S. Patent and Trademark Office) – 12:00 pm to 1:30 pm (ET)

    April 1, 2021 – "Creating Innovators" (U.S. Patent and Trademark Office and National Council for Expanding American Innovation) – 12:00 to 1:00 pm (ET)

    April 1, 2021 – "Protecting Technology in a Time of Vanishing Borders and Rising Nationalism" (Federal Circuit Bar Association) – 1:00 to 2:00 pm (ET)

    April 16, 2020 – "Strategies for Federal Circuit, District Court, ITC, and PTAB" (UIC John Marshall Law School Center for Intellectual Property, Information & Privacy Law) – 7:40 am to 3:15 pm

    April 26-27, 2021 – Paragraph IV Disputes Conference (American Conference Institute)